Defining a new aggressiveness classification and using NFATc1 localization as a prognostic factor in cherubism

Affiliation auteurs!!!! Error affiliation !!!!
TitreDefining a new aggressiveness classification and using NFATc1 localization as a prognostic factor in cherubism
Type de publicationJournal Article
Year of Publication2016
AuteursKadlub N, Sessiecq Q, Dainese L, Joly A, Lehalle D, Marlin S, Badoual C, Galmiche L, Majoufre-Lefebvre C, Berdal A, Deckert M, Vazquez M-P, Descroix V, Coudert AE, Picard A
JournalHUMAN PATHOLOGY
Volume58
Pagination62-71
Date PublishedDEC
Type of ArticleArticle
ISSN0046-8177
Mots-clésCherubism, Giant cell reparative granuloma, NFATc1, prognosis, TRAP
Résumé

Cherubism is a rare genetic disease characterized by bilateral giant cell reparative granuloma of the jaws consisting of a fibrotic stroma with giant multinucleated cells (GMCs) and osteoclastic features. Cherubism severity is highly variable, and recurrence after surgery is the most important risk. Currently, there are no prognostic indicators. The aims of this study were to evaluate the osteoclastogenesis phenotype by histologic examination of nuclear factor of activated T cells 1 (NFATc1) localization and tartrate-resistant acid phosphatase (TRAP) activity and to correlate the results to disease aggressiveness to define prognostic indicators. Based on cherubism evolution 1 year after surgery, 3 classes of cherubism aggressiveness were identified: mild (group A), moderate (group B), and severe (group C). Histologically, in grade A and B cherubism lesions, GMCs were negative for both TRAP activity and NFATcl nuclear localization. In contrast, in grade C cherubism lesions, GMCs were all positive for TRAP activity and NFATcl nuclear localization and displayed osteoclast-like features. Other histopathologic findings were not different among the 3 groups. Our results establish that TRAP activity and NFTAc1 nuclear localization are associated with aggressive cherubism and therefore could be added to routine pathologic examination to aid in prognosis and management of the disease. The finding of NFATcl nuclear localization in aggressive tumors supports the addition of anticalcineurin treatment to the therapeutic arsenal for cherubism. (C) 2016 Elsevier Inc. All rights reserved.

DOI10.1016/j.humpath.2016.07.019